Status:
RECRUITING
Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer
Lead Sponsor:
Shantou Central Hospital
Collaborating Sponsors:
Zhejiang Cancer Hospital
Sichuan Cancer Hospital and Research Institute
Conditions:
Breast Cancer
Lymph Node Metastasis
Eligibility:
FEMALE
18+ years
Brief Summary
Breast cancer is a malignant tumor with the highest morbidity and mortality among women worldwide. Accurate staging of axillary lymph nodes is critical for metastatic assessment and decisions regardin...
Eligibility Criteria
Inclusion
- Pathological diagnosis of breast cancer
- No preoperative therapy including chemotherapy or endocrine therapy
- No distant metastasis
- Underwent mastectomy or breast-conserving surgery with sentinel lymph node biopsy
- Agreed to provide preoperative peripheral blood samples
- Had access to imaging, pathological and follow-up data for preoperative and postoperative evaluation of the disease
Exclusion
- Neoadjuvant therapy
- Presence of distant metastasis at time of diagnosis
- Primary malignancies other than breast cancer
- Bilateral breast cancer or previous contralateral breast cancer
- Undergo modified radical surgery for breast cancer without sentinel lymph node biopsy
- Incomplete pathological data and follow-up data
- Pregnancy and other conditions determined by the investigator to be ineligible for inclusion in the study
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
2400 Patients enrolled
Trial Details
Trial ID
NCT06001528
Start Date
January 1 2021
End Date
August 31 2026
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shantou Central Hospital
Shantou, Guangdong, China